2019 Pipeline Report
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
Treatment Action Group Joins Collective Call Denouncing the Trump Administration’s Dangerous Finalized Anti-Immigrant Rule
Treatment Action Group (TAG) strongly opposes the administration’s finalized rule “Inadmissibility on Public Charge Grounds.” This rule, which goes into effect on October 15, 2019, dangerously expands the definition of immigrants who are ineligible for admission into the U.S. or adjustment of status to include those who seek basic public services for health, nutrition, and housing.
Low- and Middle-Income Countries Defuse Hepatitis C, the “Viral Time Bomb”
June 2013 By Karyn Kaplan As rich countries prepare for a hepatitis C virus (HCV) treatment revolution, people in low- and middle-income countries (LMICs) remain without access to information, prevention tools, diagnostics, care, and treatment. A growing movement of global…
2013 EASL Update
Streamlining HCV Treatment By Tracy Swan Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations of direct-acting antivirals (DAAs) have pushed cure rates in HCV genotype 1 to over 90 percent. Still, we are…
Hepatitis C Drug Development Catapults Onward
June 2013 By Tracy Swan Thanks to Jules Levin The pace of, and progress in, hepatitis C virus (HCV) drug development are astonishing. In April 2011, proof-of-concept for safe, effective, peginterferon-free HCV treatment was announced. Since then, numerous trials have…
Global Update: Hepatitis C Treatment Activism
By Karyn Kaplan and Tracy Swan How can governments and donors effectively address HCV if pharma refuses to drop drug prices? —Paata Sabelashvili, Activist, Georgian Harm Reduction Network Keeping up with the rapid pace of hepatitis C drug development,…
2013/2014 HCV Drug Pipeline Update
July 2014 By Tracy Swan Thanks to Jules Levin This update includes presentations from the American Association for the Study of Liver Diseases (AASLD) Meeting, the Conference on Retroviruses and Opportunistic Infections (CROI), the European Association for the Study of…
Hepatitis C Pipeline: BONANZA! The Gold Rush Is Under Way
July 2014 By Tracy Swan BONANZA! The Gold Rush Is Under Way The direct-acting antiviral (DAA) era officially began in late 2013, with approval of the first all-oral treatment for hepatitis C virus (HCV) genotypes 2 and 3. A hefty…
New Drugs, New Strategies: Conquering Hepatitis C with Direct-Acting Antivirals
July 2015 By Tracy Swan Hepatitis C has to be one of the most grossly miscalculated diseases by governments on the planet. —Michel Kazatchkine, UN secretary general’s special envoy on HIV/AIDS in Eastern Europe and Central Asia and commissioner, Global…
2016 Hepatitis C Virus (HCV) Update
July 15, 2016 By Mark Harrington Due to recent transitions in the TAG HCV Project [1], we did not complete a comprehensive update on hepatitis C virus (HCV) pipeline. Here are a few highlights in HCV regulation, access, and policy…